SUBTYPES OF MUSCARINIC RECEPTORS

简介(申请人摘要)：首届亚型研讨会 1983年举行的M受体是第一个探测一个被忽视的领域的人 几年来，除了少数几个调查人员外，所有人都这么做了。作为一项针对 治疗学的实际问题，毒碱亚型的概念 受体成为现实，整个研究领域都被注入了活力 快速增长。在第一次研讨会以来的短短时间里，已经有4个亚型 在药理特性的基础上明确定义，并已证明 是不同基因和序列、分布和 5种M受体的偶联机制已被揭示。9号 研讨会将延续以往创造的先例，增加我们的基本 M受体的知识和新的激动剂和拮抗剂的披露 具有潜在的或已证明的治疗价值的。研讨会将作为一项 中国学会年会的卫星，并与之联合举行 神经科学。主要目标是提供一个相互作用的论坛 积极研究M受体功能和 积极探索受体的身份和结构的研究人员 具有技术的亚型是从分子克隆进化而来的。要实现的广阔领域 内容包括：1)分子药理调节及功能 M受体及其与其他系统的相互作用；2)发育， 新的选择性药物的药物化学和临床方面，特别是 关于生殖-泌尿系统和胃肠系统，以及心血管 和肺功能，以及3)对毒扁豆碱作用的新见解 中枢神经系统中的受体及其与阿尔茨海默病的关系 疾病、精神分裂症、疼痛和青光眼。这次研讨会提供了一个独特的 生物化学家、生理学家、药理学家之间的互动机会 以及神经学家，他们是多学科方法的领导者 被带到现场的年轻研究人员和博士后研究员 在海报展示环节中展示他们的作品。研讨会论文集 将在2至3个月内作为生命科学和 免费发送给它的数千名订户。

DESCRIPTION (Applicant's Abstract): The First Symposium on Subtypes of Muscarinic Receptors, held in 1983, was the first to probe a field ignored for years by all but a few investigators. As a result of research directed at a practical problem of therapeutics, the concept of subtypes of the muscarinic receptor became a reality and a whole field of research was energized into rapid growth. In the short time since the first symposium 4 subtypes have been clearly defined on the basis of pharmacological properties and have been shown to be the products of distinct genes and the sequences, distribution, and coupling mechanisms of 5 muscarinic receptors have been disclosed. The Ninth Symposium will continue the precedents set previously by increasing our basic knowledge of muscarinic receptors and disclosing new agonists and antagonists of potential or demonstrated therapeutic value. The Symposium will be held as a satellite of, and in conjunction with, the annual meeting of the Society of Neurosciences. The major goals are to provide a forum for interaction between individuals who are actively studying muscarinic receptor function and investigators who are actively pursuing the identity and structure of receptor subtypes with technologies evolved from molecular cloning. The broad areas to be covered include: 1) molecular pharmacology regulation and function of muscarinic receptors and interactions with other systems; 2) development, medicinal chemistry and clinical aspects of new, selective agents, particularly with respect to genito-urinary and gastrointestinal systems, and cardiovascular and pulmonary function, and 3) new insights into the role of muscarinic receptors in the central nervous system and their relevance to Alzheimer's disease, schizophrenia, pain and glaucoma. This symposium provides an unique opportunity for interaction between biochemists, physiologists, pharmacologists and neuroscientists who are the leaders in the multidisciplinary approach being taken in the field and young investigators and predoctoral fellows who will present their work in the poster sessions. The Proceedings of the Symposium will be published within 2 to 3 months as a regular issue of Life Sciences and sent free to its thousands of subscribers.